BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 37791067)

  • 1. Modified Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab for Advanced HCC: Two Case Reports.
    Tian Y; Jin W; Sun H; Jin D; Kang D; Li Z; Piao L
    J Hepatocell Carcinoma; 2023; 10():1587-1593. PubMed ID: 37791067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
    Li X; Ding X; Liu M; Wang J; Sun W; Teng Y; Xu Y; Wu H; Li W; Zhou L; Chen J
    Cancer Med; 2023 Aug; 12(16):16805-16814. PubMed ID: 37387602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A case of advanced HCC treated with lenvatinib after hepatic arterial infusion chemotherapy combined with radiation therapy treatment for portal vein tumor thrombosis in the main trunk.
    Kosaka Y; Kawaoka T; Aikata H; Suehiro Y; Yamaoka K; Ando Y; Namba M; Takeuchi Y; Fujii Y; Uchikawa S; Kodama K; Oya K; Morio K; Fujino H; Nakahara T; Murakami E; Yamauchi M; Tsuge M; Hiramatsu A; Imamura M; Baba Y; Awai K; Kimura T; Nagata Y; Chayama K
    Clin J Gastroenterol; 2020 Oct; 13(5):839-843. PubMed ID: 31974811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of HAIC (FOLFOX) combined with lenvatinib plus PD-1 inhibitors vs. TACE combined with lenvatinib plus PD-1 inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombus and arterioportal fistulas.
    Lin Z; Chen D; Hu X; Huang D; Chen Y; Zhang J; Li X; Zou X
    Am J Cancer Res; 2023; 13(11):5455-5465. PubMed ID: 38058801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case Report: Successful conversion and salvage resection of huge hepatocellular carcinoma with portal vein tumor thrombosis and intrahepatic metastasis via sequential hepatic arterial infusion chemotherapy, lenvatinib plus PD-1 antibody followed by simultaneous transcatheter arterial chemoembolization, and portal vein embolization.
    Luo X; Chang RZ; Kuang D; Yuan M; Li GX; Zhang B; Wang YJ; Zhang WG; Ding ZY
    Front Immunol; 2023; 14():1285296. PubMed ID: 37928536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis.
    Leung JH; Wang SY; Leung HWC; Chan ALF
    Front Oncol; 2024; 14():1344798. PubMed ID: 38434681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation and efficacy of TACE combined with lenvatinib plus PD-1 inhibitor in the treatment of hepatocellular carcinoma with portal vein tumor thrombus based on immunological features.
    Zou X; Xu Q; You R; Yin G
    Cancer Med; 2023 May; 12(10):11315-11333. PubMed ID: 36951443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination Therapy of Chemoembolization and Hepatic Arterial Infusion Chemotherapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis Compared with Chemoembolization Alone: A Propensity Score-Matched Analysis.
    Liu BJ; Gao S; Zhu X; Guo JH; Kou FX; Liu SX; Zhang X; Wang XD; Cao G; Chen H; Liu P; Zhu LZ; Xu HF; Yang RJ
    Biomed Res Int; 2021; 2021():6670367. PubMed ID: 34337041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety analysis of TACE + PEI + lenvatinib compared with TACE + lenvatinib for the treatment of hepatocellular carcinoma with PVTT: a retrospective study.
    Lu H; Zheng C; Liang B; Xia X; Fan H
    Front Oncol; 2024; 14():1280837. PubMed ID: 38298738
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial.
    Hu Y; Qin T; Li S; Zhang T; Xue J
    Front Oncol; 2020; 10():1589. PubMed ID: 32984021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of transcatheter arterial chemoembolization plus hepatic arterial infusion chemotherapy in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.
    Wu Z; Gao J; Zhuang W; Yang J; Guo W
    J Cancer Res Ther; 2022 Apr; 18(2):345-351. PubMed ID: 35645099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.
    Chen R; Li Y; Song K; Li L; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Apr; 13(2):780-786. PubMed ID: 35557575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A prospective randomized study.
    Ding X; Sun W; Li W; Shen Y; Guo X; Teng Y; Liu X; Zheng L; Li W; Chen J
    Cancer; 2021 Oct; 127(20):3782-3793. PubMed ID: 34237154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretreatment Neutrophil-to-Lymphocyte Ratio as Prognostic Biomarkers in Patients with Unresectable Hepatocellular Carcinoma Treated with Hepatic Arterial Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab.
    Xiao Y; Zhu G; Xie J; Luo L; Deng W; Lin L; Tao J; Hu Z; Shan R
    J Hepatocell Carcinoma; 2023; 10():2049-2058. PubMed ID: 37965074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The treatment of transarterial chemoembolization/hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor is effective against hepatocellular carcinoma with portal vein tumor thrombus: A systematic review.
    Yuanren G; Yin L; Liu R; Cui Y
    Front Oncol; 2023; 13():1054072. PubMed ID: 36969065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Sorafenib, Camrelizumab, Transcatheter Arterial Chemoembolization, and Stereotactic Body Radiation Therapy as a Novel Downstaging Strategy in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Case Series Study.
    Huang Y; Zhang Z; Liao W; Hu K; Wang Z
    Front Oncol; 2021; 11():650394. PubMed ID: 34408974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients.
    Liu J; Li Z; Zhang W; Lu H; Sun Z; Wang G; Han X
    Front Pharmacol; 2021; 12():709060. PubMed ID: 34733154
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Yuan G; Cheng X; Li Q; Zang M; Huang W; Fan W; Wu T; Ruan J; Dai W; Yu W; Chen M; Guo Y; Hu X; Chen J
    Onco Targets Ther; 2020; 13():12683-12693. PubMed ID: 33328740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study.
    Chen S; Shi F; Wu Z; Wang L; Cai H; Ma P; Zhou Y; Mai Q; Wang F; Tang S; Zhuang W; Lai J; Chen X; Chen H; Guo W
    J Hepatocell Carcinoma; 2023; 10():1209-1222. PubMed ID: 37533600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.